Jinyu Bio-Technology Co Ltd (SHG:600201) — Market Cap & Net Worth
Market Cap & Net Worth: Jinyu Bio-Technology Co Ltd (600201)
Jinyu Bio-Technology Co Ltd (SHG:600201) has a market capitalization of $2.37 Billion (CN¥16.22 Billion) as of May 4, 2026. Listed on the SHG stock exchange, this China-based company holds position #5641 globally and #1163 in its home market, demonstrating a 2.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jinyu Bio-Technology Co Ltd's stock price CN¥14.59 by its total outstanding shares 1111747826 (1.11 Billion). Analyse Jinyu Bio-Technology Co Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Jinyu Bio-Technology Co Ltd Market Cap History: 2015 to 2026
Jinyu Bio-Technology Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.00 Billion to $2.37 Billion (0.09% CAGR).
Jinyu Bio-Technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jinyu Bio-Technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.89x
Jinyu Bio-Technology Co Ltd's market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
10.24x
Jinyu Bio-Technology Co Ltd's market cap is 10.24 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.00 Billion | $1.25 Billion | $479.73 Million | 2.41x | 6.25x |
| 2016 | $2.60 Billion | $1.52 Billion | $644.54 Million | 1.71x | 4.04x |
| 2017 | $3.71 Billion | $1.90 Billion | $870.09 Million | 1.95x | 4.27x |
| 2018 | $2.57 Billion | $1.90 Billion | $754.47 Million | 1.35x | 3.40x |
| 2019 | $2.96 Billion | $1.13 Billion | $221.04 Million | 2.63x | 13.40x |
| 2020 | $3.31 Billion | $1.58 Billion | $406.20 Million | 2.09x | 8.15x |
| 2021 | $2.61 Billion | $1.78 Billion | $382.29 Million | 1.47x | 6.83x |
| 2022 | $1.46 Billion | $1.53 Billion | $210.66 Million | 0.95x | 6.91x |
| 2023 | $1.75 Billion | $1.60 Billion | $283.63 Million | 1.10x | 6.18x |
| 2024 | $1.12 Billion | $1.26 Billion | $108.99 Million | 0.89x | 10.24x |
Competitor Companies of 600201 by Market Capitalization
Companies near Jinyu Bio-Technology Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Jinyu Bio-Technology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Jinyu Bio-Technology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jinyu Bio-Technology Co Ltd's market cap moved from $3.00 Billion to $ 2.37 Billion, with a yearly change of 0.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥2.37 Billion | -3.19% |
| 2025 | CN¥2.45 Billion | +119.68% |
| 2024 | CN¥1.12 Billion | -36.30% |
| 2023 | CN¥1.75 Billion | +20.30% |
| 2022 | CN¥1.46 Billion | -44.21% |
| 2021 | CN¥2.61 Billion | -21.19% |
| 2020 | CN¥3.31 Billion | +11.86% |
| 2019 | CN¥2.96 Billion | +15.29% |
| 2018 | CN¥2.57 Billion | -30.83% |
| 2017 | CN¥3.71 Billion | +42.75% |
| 2016 | CN¥2.60 Billion | -13.29% |
| 2015 | CN¥3.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Jinyu Bio-Technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.37 Billion USD |
| MoneyControl | $2.37 Billion USD |
| MarketWatch | $2.37 Billion USD |
| marketcap.company | $2.37 Billion USD |
| Reuters | $2.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company operates through three segments, such as veterinary biological products, veterinary chemical drugs, and traditional Chinese veterinary medicines. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined … Read more